In Otero Balda 2025 et al., on Short-term outcomes after feline cPSS surgery, which clinical variable was associated with the **lowest** odds of 30-day survival?
A. Development of non-seizure PANS
B. Treatment with levetiracetam
C. Treatment with propofol
D. Shunt location (intrahepatic)
E. Use of thin film banding
Answer: Treatment with propofol
Explanation: Propofol use was a negative prognostic factor (OR 0.112, p = .0008), likely reflecting more severe disease.
In Otero Balda 2025 et al., on Short-term outcomes after feline cPSS surgery, what was the 30-day survival rate in cats that developed postattenuation neurologic signs (PANS) after surgical attenuation of a single congenital portosystemic shunt?
A. 46%
B. 50%
C. 60%
D. 78%
E. 90%
Answer: 78%
Explanation: The study reported a 30-day survival rate of 78% in PANS-affected cats.
In Otero Balda 2025 et al., on Short-term outcomes after feline cPSS surgery, what was the survival rate in cats pretreated with levetiracetam following the LEV1 protocol?
A. 60.6%
B. 70.0%
C. 88.9%
D. 94.4%
E. 100.0%
Answer: 100.0%
Explanation: Cats in LEV1 group had a 100% 30-day survival rate, although the difference was not statistically significant.
In Otero Balda 2025 et al., on Short-term outcomes after feline cPSS surgery, which of the following was **not** significantly associated with 30-day survival in PANS-affected cats?
A. Shunt morphology
B. Treatment with propofol
C. Presence of generalized PAS
D. Postoperative development of seizures
E. Non-seizure neurologic signs
Answer: Shunt morphology
Explanation: Shunt type (extrahepatic vs. intrahepatic) was not significantly linked to 30-day survival in this study.
In Otero Balda 2025 et al., on Short-term outcomes after feline cPSS surgery, what proportion of cats with postattenuation seizures (PAS) survived to 30 days?
A. 25%
B. 33%
C. 50%
D. 67%
E. 80%
Answer: 50%
Explanation: Only half of the cats that developed PAS survived 30 days, compared to 78% overall.